Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria :~* Aged 4-6 years inclusive on the day of inclusion~* Child having completed the three-dose vaccination and the booster vaccination with DTacP-IPV//PRP\~T combined vaccine (PENTAXIM™) of the study E2I34~* Informed consent form signed by the parent(s) or other legal representative~* Able to attend all scheduled visits and to comply with all trial procedures~Exclusion Criteria :~* Participation in another clinical trial in the 4 weeks preceding the trial inclusion~* Planned participation in another clinical trial during the present trial period~* Congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy~* Systemic hypersensitivity to any of the vaccine components or history of a life threatening reaction to the trial vaccine or a vaccine containing the same substances~* Chronic illness at a stage that could interfere with trial conduct or completion~* Blood or blood-derived products received in the past or current or planned administration during the trial (including immunoglobulins)~* Any vaccination in the 4 weeks preceding the trial vaccination~* History of diphtheria, tetanus, pertussis, poliomyelitis infection (confirmed either clinically, serologically or microbiologically)~* Clinical or known serological evidence of systemic illness including Hepatitis B, Hepatitis C and/or Human immunodeficiency virus (HIV) infection~* Previous vaccination against the diphtheria, tetanus, pertussis, poliomyelitis diseases infection with the trial vaccine or another vaccine after completion of previous study E2I34~* Thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination~* History of/current major neurological diseases or seizures~* Febrile illness (temperature ≥ 38°C) or acute illness on the day of inclusion.~* Serious or severe reaction after a previous dose of any vaccine containing pertussis antigen, such as~* encephalopathy (with or without convulsions) in the 7days following previous administration of a pertussis containing vaccine,~* temperature more than 39.5°C within 48 hours following vaccine injection, not due to another identifiable cause~* inconsolable crying equal or more than 3 hours within 48 hours following vaccine injection,~* hypotonic hyporesponsive episode within 48 hours following vaccine injection,~* seizures with or without fever within 3 days following vaccine injection.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 6 Years
- Healthy Volunteers: t

Study Arms:
- Study Group (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).